ARTELO BIOSCIENCES, INC. Marketable Securities, Gain (Loss)
ARTELO BIOSCIENCES, INC. (ARTL) reported Marketable Securities, Gain (Loss) of $63.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLoss · last filed 2024-11-12
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for the quarter ending 2024-09-30 was $63.00K, a 61.82% decline year-over-year.
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for the quarter ending 2024-06-30 was $79.00K, a 57.30% decline year-over-year.
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for the quarter ending 2024-03-31 was $106.00K, a 14.52% decline year-over-year.
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for the quarter ending 2023-12-31 was $167.00K, a 21.90% increase year-over-year.
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for fiscal 2023 was $641.00K, a 209.66% increase from fiscal 2022.
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for fiscal 2022 was $207.00K.
- ARTELO BIOSCIENCES, INC. marketable securities, gain (loss) for fiscal 2021 was $2.00K.
| Period end | Marketable Securities, Gain (Loss) 3 month | Marketable Securities, Gain (Loss) 3 month as first filed | Marketable Securities, Gain (Loss) 4 month | Marketable Securities, Gain (Loss) 6 month | Marketable Securities, Gain (Loss) 9 month | Marketable Securities, Gain (Loss) 12 month | Marketable Securities, Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $63.00K 10-Q · filed 2024-11-12 | $142.00K derived: sum of 2 quarters · filed 2024-11-12 | $248.00K 10-Q · filed 2024-11-12 | $415.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2024-06-30 | $79.00K 10-Q · filed 2024-08-13 | $185.00K 10-Q · filed 2024-08-13 | $352.00K derived: sum of 3 quarters · filed 2024-08-13 | $517.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2024-03-31 | $106.00K 10-Q · filed 2024-05-13 | $273.00K derived: sum of 2 quarters · filed 2024-05-13 | $438.00K derived: sum of 3 quarters · filed 2024-11-12 | $623.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $332.00K derived: sum of 2 quarters · filed 2024-11-12 | $517.00K derived: sum of 3 quarters · filed 2024-11-12 | $641.00K 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $165.00K 10-Q · filed 2024-11-12 | $350.00K derived: sum of 2 quarters · filed 2024-11-12 | $474.00K 10-Q · filed 2024-11-12 | $611.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $185.00K 10-Q · filed 2024-08-13 | $309.00K 10-Q · filed 2024-08-13 | $446.00K derived: sum of 3 quarters · filed 2024-08-13 | $515.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $124.00K 10-Q · filed 2024-05-13 | -$124.00K 10-Q · filed 2023-05-11 | $261.00K derived: sum of 2 quarters · filed 2024-05-13 | $330.00K derived: sum of 3 quarters · filed 2024-05-13 | $311.00K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $206.00K derived: sum of 2 quarters · filed 2024-03-25 | $187.00K derived: sum of 3 quarters · filed 2024-03-25 | $207.00K 10-K · filed 2024-03-25 | -$207.00K 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $69.00K 10-Q · filed 2023-11-13 | $50.00K derived: sum of 2 quarters · filed 2023-11-13 | $70.00K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.00K 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $20.00K 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | -$6.00K 10-K · filed 2023-03-31 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $2.00K 10-Q · filed 2022-11-08 | |||||
| 2021-08-31 | -$319.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $665.00 derived: sum of 2 quarters · filed 2023-03-31 | $2.00K derived: sum of 3 quarters · filed 2023-03-31 | $2.00K 10-K · filed 2023-03-31 | |||
| 2021-05-31 | $984.00 10-Q · filed 2021-07-12 | $2.32K derived: sum of 2 quarters · filed 2021-07-12 | $2.32K 10-Q · filed 2021-07-12 | ||||
| 2021-02-28 | $1.33K 10-Q · filed 2021-04-13 | $1.33K 10-Q · filed 2021-04-13 | |||||
| 2020-02-29 | $0.00 10-Q · filed 2021-04-13 | $0.00 10-Q · filed 2021-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |